Bimatoprost as a Treatment for Graves' Orbitopathy

Early Phase 1

Recruiting

• Conditions: Graves Ophthalmopathy
• Interventions: Drug: Bimatoprost Ophthalmic

• Registration Number: NCT03708627
• Lead Sponsor: Johns Hopkins University

Brief Summary

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-01
• Study First Submitted: 2018-10-13
• Study First Submitted QC: 2018-10-13
• Study First Posted: 2018-10-17
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-17
• Last Update Posted: 2024-07-18
• Primary Completion: 2028-07-01
• Study Completion: 2030-07-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

Graves' Ophthalmopathy with Exophthalmos/Proptosis -

Exclusion Criteria

Active Graves Disease, Currently pregnant, Taking Steroids

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Bimatoprost in more proptotic eye	Bimatoprost Ophthalmic	Patients instill Bimatoprost in their more proptotic eye one nightly

Primary Outcome Measures

Name	Time	Method
Reduction in periorbital fat causing improvement in proptosis	1 year

Trial Locations

Locations (1)

University of Washington; 🇺🇸 Seattle, Washington, United States